These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 3497459)

  • 1. Lymphokine-activated killer (LAK) cells can be focused at sites of tumor growth by products of macrophage activation.
    Migliori RJ; Gruber SA; Sawyer MD; Hoffman R; Ochoa A; Bach FH; Simmons RL
    Surgery; 1987 Aug; 102(2):155-62. PubMed ID: 3497459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.
    Mulé JJ; Shu S; Rosenberg SA
    J Immunol; 1985 Jul; 135(1):646-52. PubMed ID: 3889158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
    Lafreniere R; Rosenberg SA
    J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2.
    Rosenberg SA; Mulé JJ
    Surgery; 1985 Sep; 98(3):437-44. PubMed ID: 3898451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
    Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
    Ettinghausen SE; Rosenberg SA
    Cancer Res; 1986 Jun; 46(6):2784-92. PubMed ID: 3486038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
    Rosenberg SA
    J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.
    Ettinghausen SE; Lipford EH; Mulé JJ; Rosenberg SA
    J Immunol; 1985 Nov; 135(5):3623-35. PubMed ID: 3900213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmentation of interleukin-2 immunotherapeutic effects by lymphokine-activated killer cells and allogeneic stimulation in murine tumor cells.
    Eggermont AM; Steller EP; Ottow RT; Matthews W; Sugarbaker PH
    J Natl Cancer Inst; 1987 Nov; 79(5):983-90. PubMed ID: 3500357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
    Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local conditions in the host influence immunotherapy with interleukin-2 and LAK cells.
    Steller EP; Ottow RT; Eggermont AM; Marquet RL; Sugarbaker PH
    Cancer Detect Prev; 1988; 12(1-6):81-90. PubMed ID: 3263202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.
    Mulé JJ; Shu S; Schwarz SL; Rosenberg SA
    Science; 1984 Sep; 225(4669):1487-9. PubMed ID: 6332379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
    Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
    Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy of advanced solid tumors in mice using chemotherapy in combination with interleukin-2 with and without lymphokine-activated killer cells.
    Kedar E; Ben-Aziz R; Shiloni E
    Isr J Med Sci; 1988; 24(9-10):494-504. PubMed ID: 3264551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.
    Mazumder A; Rosenberg SA
    J Exp Med; 1984 Feb; 159(2):495-507. PubMed ID: 6141211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice.
    Papa MZ; Vetto JT; Ettinghausen SE; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Nov; 46(11):5618-23. PubMed ID: 3489525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
    Lafreniere R; Rosenberg SA
    Cancer Res; 1985 Aug; 45(8):3735-41. PubMed ID: 3893689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.